Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,156 active trials54 approved drugs532 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06791005 | A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. | recruiting | Phase 3 | 400 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06791070 | A Study of RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum(RC48&J for EPD) | recruiting | Phase 2 | 20 | Fujian Medical University Union HospitalOTHER | 1 |
| Jan 24, 2025 |
| clinicaltrials |
| NCT05475678 | Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer | recruiting | Phase 2 | 369 | Zhenzhen LiuOTHER_GOV | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06788353 | Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma | recruiting | — | 500 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06334965 | Multi-modal Characterisation of Hepatocellular Carcinoma (HCC) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort(OPERANDI-HCC) | recruiting | N/A | 180 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06489197 | AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06645951 | Institution of an Italian Multicenter Database of Patients with Parathyroid Carcinoma or Atypical Parathyroid Adenoma | recruiting | — | 300 | F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo SettoreOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06782555 | A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab | recruiting | Phase 1 / Phase 2 | 71 | ImmunoGenesisINDUSTRY | 1 | Jan 21, 2025 | clinicaltrials |
| NCT06087614 | Dose Escalation Using Hypoxia-adjusted Radiotherapy(DE-HyART) | recruiting | Phase 2 | 124 | Rajiv Gandhi Cancer Institute & Research Center, IndiaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06780826 | A Study on the Efficacy of Atezolizumab Combined with Chemotherapy | recruiting | — | 1,430 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT04846933 | Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC(DECIDER) | recruiting | N/A | 200 | Turku University HospitalOTHER_GOV | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06777017 | Can Hepatic-splenic Elastography Predict the Risk of Hepatocellular Recurrence After Radiofrequency Ablation?(ELASTORFA) | recruiting | — | 50 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06777082 | Role of RPL8 Protein Alterations in High-grade Serous Ovarian Carcinoma(OVCAR) | recruiting | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06679816 | Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors | recruiting | Phase 4 | 882 | Beijing Tiantan HospitalOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06622031 | TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT | recruiting | N/A | 42 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06492005 | A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 2 | 160 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06767579 | Comparison of the Incidence of Delirium Caused by Different Anesthetic Agents in Patients Undergoing Liver Transplantation | recruiting | — | 350 | Yonsei UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06769971 | Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC | recruiting | Phase 2 | 80 | Sichuan UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04615143 | Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC(TALENT) | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06766643 | Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer | recruiting | Phase 2 | 130 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06762782 | Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery | recruiting | Phase 2 | 276 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04803994 | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | recruiting | Phase 3 | 434 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 6 | Jan 7, 2025 | clinicaltrials |
| NCT06480864 | Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer | recruiting | N/A | 38 | Yunpeng LiuOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06754059 | Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC | recruiting | — | 60 | zhangjieOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06755762 | Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer | recruiting | — | 88 | Chang Gung Memorial HospitalOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT01954992 | Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | recruiting | Phase 3 | 480 | Eleison Pharmaceuticals LLC.INDUSTRY | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05613478 | Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma | recruiting | Phase 3 | 130 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06446154 | Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06725576 | Ultrasound-Guided Microwave Ablation Vs. Surgery for Low-Risk PapilaryThyroid Carcinoma | recruiting | — | 201 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05214222 | Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma(ANSWER) | recruiting | Phase 2 | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06653062 | Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance(CCGLC-015) | recruiting | — | 50 | Tongji HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06748352 | Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer | recruiting | N/A | 50 | Shandong UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06749691 | Liposomal Irinotecan and Apatinib in ES-SCLC(LIAES) | recruiting | Phase 2 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06750419 | 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study | recruiting | Phase 3 | 82 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06405490 | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06689540 | Mts105 for Advanced Hepatocellular Carcinoma(MTS105 for HCC) | recruiting | Phase 1 | 14 | Shen LinOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06746194 | The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy | recruiting | — | 40 | Ruijin HospitalOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT05359939 | A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma | recruiting | N/A | 50 | University of AarhusOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05871892 | 18F-FDGal PET/CT and PET/MRI in Patients With Hepatocellular Carcinoma | recruiting | N/A | 125 | University of AarhusOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05877430 | Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 160 | CJ Bioscience, Inc.INDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT06684327 | Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors | recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06745830 | Lymph Node Pathologic Grading Strategy | recruiting | — | 2,998 | Fudan UniversityOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT06281678 | A Study of IBI363 in Subjects with Advanced Solid Malignancies | recruiting | Phase 2 | 178 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06741982 | A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus | recruiting | Phase 1 | 21 | West China HospitalOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06349980 | A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients. | recruiting | Phase 2 | 117 | Shanghai Henlius BiotechINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06730672 | An Exploratory Study on the Failure of Immunotherapy With Voronib Combined With Everolimus | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06276868 | Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer | recruiting | Phase 2 | 71 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06440057 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. | recruiting | Phase 1 / Phase 2 | 78 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 16, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 24, 2025source: clinicaltrials